Breast- L-FABP negative invasive breast cancer of no special type (NST).

Breast- L-FABP negative invasive lobular breast cancer.

Colon- Colorectal adenocarcinoma with moderate to strong L-FABP immunostaining of >50% of tumor cells.

Colon- Colorectal adenocarcinoma with very strong L-FABP immunostaining of tumor cells. Contamination (spill over) artifact leads to significant staining of adjacent tumor stroma.

Colon- L-FABP negative colorectal adenocarcinoma.

Esophagus- Adenocarcinoma with focal moderate to strong L-FABP immunostaining of tumor cells.

Kidney- Clear cell renal cell carcinoma with weak to moderate L-FABP immunostaining of about 30-40% of tumor cells.

Kidney- Papillary renal cell carcinoma with focal moderate L-FABP immunostaining of <5% of tumor cells.

Lymph node- L-FABP negative Hodgkin’s lymphoma.

Ovary- L-FABP negative clear cell carcinoma.

Ovary- L-FABP negative serous high-grade carcinoma.

Ovary- Mucinous carcinoma with strong L-FABP immunostaining of tumor cells.

Pancreas- Adenocarcinoma of the papilla Vaterii with strong L-FABP immunostaining of >95% of tumor cells.

Pancreas- Ductal adenocarcinoma with moderate L-FABP immunostaining of 5-10% of tumor cells.

Pancreas- L-FABP negative ductal adenocarcinoma.

Pancreas- L-FABP negative neuroendocrine tumor.

Penis- L-FABP negative squamous cell carcinoma.

Pharynx- L-FABP negative squamous cell carcinoma.

Prostate- L-FABP negative adenocarcinoma (Gleason 3+3=6).

Skin- L-FABP negative Merkel cell carcinoma.

Soft tissue- L-FABP negative leiomyosarcoma.

Soft tissue- L-FABP negative liposarcoma.

Stomach- L-FABP negative gastrointestinal stromal tumor (GIST).

Testis- L-FABP negative Leydig cell tumor.

Testis- L-FABP negative seminoma.

Thyroid- L-FABP negative medullary carcinoma.

Thyroid- L-FABP negative papillary carcinoma.

Uterus- Endometrium carcinoma with very strong L-FABP immunostaining of tumor cells. Contamination (spill over) artifact leads to significant staining of adjacent tumor stroma.

Vagina- L-FABP negative squamous cell carcinoma.